Company profile: Neutec Pharma
1.1 - Company Overview
Company description
- Provider of biopharmaceuticals developing and manufacturing genetically recombinant antibody therapies and platform technologies. Products include Mycograb targeting heat shock protein 90 for systemic candidiasis; Aurograb targeting Staphylococcus aureus, including MRSA and VISA, used with vancomycin for MRSA; and FABTEC, a platform for identifying new therapeutic antibody fragments.
Products and services
- Aurograb: A genetically recombinant antibody targeting Staphylococcus aureus, including MRSA and VISA, used with vancomycin for treating MRSA infections
- FABTEC: A platform technology for identifying new therapeutic antibody fragments via recruitment of individuals, amplification, cloning, sequencing, and laboratory-scale production of antibody fragments
- Mycograb: A genetically recombinant antibody targeting heat shock protein 90 (hsp90) for the treatment of systemic candidiasis, a life-threatening fungal infection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Neutec Pharma
Cormorant Pharma
HQ: Sweden
Website
- Description: Provider of biopharmaceutical research and development focused on IL-8's role in malignant tumors, including the HuMax-IL8 program acquired from Genmab A/S. The privately held company is based at the Karolinska Institute Science Park in Stockholm, Sweden.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cormorant Pharma company profile →
MultiCell Technologies
HQ: United States
Website
- Description: Provider of biopharmaceutical solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MultiCell Technologies company profile →
Advaxis
HQ: United States
Website
- Description: Provider of clinical-stage immunotherapies for cancer and infectious diseases, based on a proprietary platform using live, attenuated bacteria engineered to secrete antigen/adjuvant fusion proteins to redirect the immune system to target and kill cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advaxis company profile →
Affinivax
HQ: United States
Website
- Description: Provider of vaccine R&D targeting infectious diseases, using its MAPS (Multiple Antigen Presenting System) platform to enable broader coverage by combining polysaccharides and proteins. Offerings include AFX3772, a 24-valent pneumococcal vaccine candidate in phase II for S. pneumoniae prevention in adults and children, and a 30-plus valent pneumococcal candidate in pre-clinical development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Affinivax company profile →
Alexion
HQ: United States
Website
- Description: Provider of biologic therapies for severe, life-threatening diseases, including hematologic, kidney and neurologic conditions, transplant rejection, cancer and autoimmune disorders; portfolio includes SOLIRIS (PNH, aHUS, NMOSD), ULTOMIRIS (PNH, aHUS), STRENSIQ (HPP) and KANUMA (LAL-D), plus patient support and managed access programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alexion company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Neutec Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Neutec Pharma
2.2 - Growth funds investing in similar companies to Neutec Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Neutec Pharma
4.2 - Public trading comparable groups for Neutec Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →